Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder

This study has been completed.
Sponsor:
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00036101
First received: May 7, 2002
Last updated: November 7, 2013
Last verified: September 2007

May 7, 2002
November 7, 2013
February 2002
January 2003   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00036101 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder
Not Provided

The purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of Bipolar disorder.

Not Provided
Interventional
Phase 3
Primary Purpose: Treatment
Bipolar Disorder
Drug: aripiprazole
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
January 2003
January 2003   (final data collection date for primary outcome measure)

Inclusion Criteria:

Patients with acute symptoms of Bipolar Disorder

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00036101
CN138-074
Not Provided
Not Provided
Otsuka Pharmaceutical Development & Commercialization, Inc.
Not Provided
Not Provided
Otsuka Pharmaceutical Development & Commercialization, Inc.
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP